MXCT News and Press, MaxCyte Inc. From 03/15/23

2023-03-15 21:41:35 ET The following slide deck was published by MaxCyte, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: MaxCyte, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-15 21:41:02 ET MaxCyte, Inc. (MXCT) Q4 2022 Earnings Conference Call March 15, 2023 16:30 ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Ron Holtz - Interim Chief Financial Officer C...

2023-03-15 16:11:09 ET MaxCyte press release ( NASDAQ: MXCT ): Q4 GAAP EPS of -$0.05 beats by $0.02 . Revenue of $10.88M (+7.2% Y/Y) misses by $2.25M . Initial 2023 guidance for total revenue growth of 21% to 26% over 2022, including core revenue growth of 20% ...

ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innova...

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to supp...

2023-03-06 18:12:13 ET MaxCyte ( NASDAQ: MXCT ) on Monday announced expectations for Q4 and FY 2022 revenue that came in below estimates. The company said it anticipated Q4 revenue to be about $12.4M, compared to a consensus figure of $13.14M. FY 2022 revenue is ex...

Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021 Fourth quarter 2022 total revenue expected to be approximately $12.4 million, representing growth of 22% over fourth quarter 2021 Installed base at year end 2022...

ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovati...

Summary BAMCO’s 13F portfolio value decreased from $31.14B to $30.95B this quarter. Ron Baron decreased Rivian Automotive and Alphabet during the quarter. Their top five positions are at ~31% of the overall portfolio. This article is part of a series that provides an on...

ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and...